TMDX— AI Stock Forecast & Price Targets
Published 6/30/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live TMDX price forecast →
TMDX presents a compelling fundamental story anchored by its proprietary OCS platform and strong historical growth (30% TTM revenue growth), but the stock is currently battling significant negative momentum and valuation concerns relative to its highs. The technical picture shows deep retracement, suggesting caution despite positive analyst commentary on the core technology.
Wait for a clear technical bounce or consolidation pattern above key support levels identified on the 1-day chart. Given the low short-term directional accuracy (26%), any entry should be treated as high-risk, potentially using defined stop-losses below recent lows.
The mid-term thesis remains positive based on OCS adoption and revenue growth momentum. The base target of $95.00 (from prior analysis) is significantly higher than the current price, suggesting substantial upside if execution continues. Catalysts include successful integration/adoption of OCS across more transplant centers.
The long-term thesis rests on TMDX becoming a standard component of organ care infrastructure. The biggest structural risk remains the high debt load and the ability to translate strong revenue growth into sustained, profitable free cash flow without excessive capital expenditure.
The company exhibits strong underlying operational metrics: total revenue of $635.9M and a high Return on Equity (ROE) of 45.2%. Quarterly earnings show improving profitability trends, with operating margins reaching 23.2% in Q2 2026. Cash flow generation has been robust recently ($91.6B FCF in Q2 2026), indicating strong operational cash conversion. However, the balance sheet shows a high Debt/Equity ratio of 174.8, which is a significant overhang that must be managed alongside continued capital expenditure.
The stock has experienced a severe downtrend, falling significantly from its 52-week high of $156 to the current level near $67. The chart patterns show multiple support tests in the recent past (visible on both timeframes), suggesting potential consolidation or mean reversion plays are being priced in by some traders. The model's short-term directional accuracy is low (26% vs 74% baseline), indicating high uncertainty, while the yellow forecast band suggests a range that has been significantly breached downwards.
The news flow highlights TMDX's core strength—the OCS platform for organ preservation—and its strong growth profile. Analyst coverage remains positive on the technology (e.g., Stifel raising PT to $80), and recent articles frame it as an 'Affordable Growth Stock.' The primary noise comes from insider selling ($722k sale) and general market volatility, which has pressured the stock price despite solid fundamentals.
- Expansion of OCS platform utilization: Continued adoption of OCS LUNG, Heart, and Liver across various transplant centers is the primary driver for top-line revenue growth.
- Operational Services Growth: The development of the national OCS program and associated logistics services provide a recurring revenue stream beyond core device sales.
- High Debt/Equity ratio (174.8) poses significant financial risk, especially if cash flow falters or interest rates rise.
- Valuation compression: The stock has fallen nearly 50% from its peak, suggesting that market sentiment may be pricing in severe execution risks despite positive fundamentals.
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord